James Maitland brings years of deep-seated experience in medical robotics and the Internet of Things (IoT) to the healthcare venture capital landscape. Driven by a passion for how technical innovation can solve ancient clinical inefficiencies, he has witnessed the market’s evolution from the frantic post-pandemic surge to the more calculated, AI-driven rebound we see today. In this discussion, we explore the significant uptick in digital health funding, which reached $7.4 billion in the first half of 2026, and how a concentrated group of high-value megadeals is reshaping the competitive landscape. We also delve into the shifting requirements for a sustainable “moat” in an era where AI is ubiquitous, the rise of GLP-1 adjacent markets, and the accelerating pace of mergers and acquisitions as companies prepare for a potential reopening of the IPO window.
The first half of 2026 has seen a notable resurgence in digital health investment. How do you interpret this $7.4 billion influx compared to previous years, and what does it tell us about the market’s current appetite?
The numbers we are seeing right now signal a very healthy rebound after the market spent much of 2023 finding its footing again. Raising $7.4 billion in just six months—a full billion dollars more than the $6.4 billion we saw in the first half of 2025—proves that investors have moved past their initial hesitation and are now aggressively backing clear winners. While the $3.2 billion raised in the second quarter was slightly lower than the $4.2 billion from the first quarter, the momentum is undeniably there across the 244 deals we tracked. What is most fascinating is how this capital is being deployed; it isn’t being spread thin across a thousand experiments, but rather concentrated into high-conviction bets. This indicates that the “reset” is over and we have entered a phase where the market is rewarding companies that can demonstrate both technical maturity and a path to scaling in a post-pandemic world.
We are noticing that a very small percentage of deals are absorbing nearly half of all the capital. What is driving this concentration of wealth into these massive “megadeals,” and what are some standout examples?
We are currently seeing a “winner-takes-most” dynamic where a tiny fraction of companies—specifically 8% of deals—are capturing about 45% of the total capital deployed. In the first half of this year, 19 companies secured 20 megadeals of $100 million or more, which tells you that venture capitalists are looking for established leaders who can handle enormous scale. You see this with Whoop securing $575 million and Verily picking up $300 million, but perhaps more telling are the back-to-back rounds where investors are doubling down on success. For instance, Garner Health raised a $100 million Series E just three months after a $118 million Series D, and the clinical AI platform Aidoc managed to clinch its second $150 million check in less than a year. This level of rapid-fire funding for companies like OpenEvidence, Talkiatry, and eMed shows that if you have the data and the traction, the capital is essentially limitless right now.
As AI becomes a standard feature rather than a luxury, the criteria for what makes a company “investable” are shifting. How are you advising founders to build a “moat” when technical differentiation is becoming harder to maintain?
The days of simply having “AI” as your core value proposition are officially over because foundation models have made basic AI capabilities much easier to build and replicate. Investors are no longer asking who has the best algorithm, but rather who has the domain expertise and the integrated workflow that a generic AI model cannot touch. To build a durable advantage today, you have to “own” more of the clinical workflow, which provides the necessary context to coordinate complex healthcare tasks that agentic AI alone would struggle with. We are also seeing a major shift toward “hands-on delivery” through forward-deployed engineers, where companies like Commure and Qualified Health send technical experts to live within a client’s environment to co-develop custom workflows. It’s that white-glove service combined with deep partnerships—like Abridge’s work with Nvidia and various medical societies—that creates a network effect that is incredibly difficult for a newcomer to disrupt.
Mental health and weight management continue to dominate the clinical funding charts. What is fueling the sustained interest in these specific areas, and are there any emerging sub-sectors we should watch?
Mental health remains the heavyweight champion of clinical indications, as evidenced by the massive rounds for Talkiatry and Grow Therapy, as well as smaller but significant raises like Jimini Health’s $17 million and The Path’s $14.3 million. However, the weight management and obesity sector has become a powerhouse in its own right, largely driven by the explosive demand for GLP-1 medications. We saw three major megadeals in this space alone in 2026, with eMed raising $200 million while both Nourish and Midi secured $100 million each to scale their ecosystems around these treatments. What is even more exciting from an investment perspective is the “halo effect” this is having on adjacent peptide categories. We are starting to see real capital flowing into experimental peptides for wellness and longevity, with Superpower raising $30 million and smaller players like Protocole and Feel Peptides starting to gain traction as they look for the next big breakthrough beyond traditional weight loss.
With no major IPOs yet in 2026, the industry is closely watching the exit landscape. How are companies navigating this, and what does the current M&A activity suggest about the future of the sector?
While we are still waiting for that first big “bellwether” IPO of 2026, the pipeline is incredibly crowded with companies like Oura, Whoop, and Virta Health clearly getting their books in order to go public. In the meantime, the M&A market has stepped up to provide the necessary liquidity, with 115 acquisitions occurring in the first half of the year alone, which is a significant jump from the 121 deals we saw in all of 2024. Revenue cycle management (RCM) has become a particularly hot bed for consolidation; we’ve seen IKS Health acquire TruBridge to reach rural markets, and Innovaccer folding CaduceusHealth into its platform to broaden its reach. Even the private equity players are making massive moves, exemplified by the Thoreau Group’s staggering $12 billion agreement to acquire Ensemble Health. This level of consolidation suggests that the market is maturing, and the largest players are aggressively buying up specialized tools to create all-in-one healthcare operating systems.
What is your forecast for the digital health sector as we head into the second half of the year and 2027?
I expect the focus to shift entirely from the “what” of technology to the “how” of integration, where the ultimate winners will be those who can prove they reduce the administrative burden on clinicians while improving patient outcomes. We will likely see a handful of those high-profile IPOs from the likes of Maven Clinic or Spring Health finally break through, which will provide a much-needed confidence boost to late-stage investors. The trend of megadeals will continue as capital seeks the safety of scale, but we will also see a new wave of “AI-native” startups that don’t just add a chatbot to an old process but completely reinvent how care is delivered from the ground up. Ultimately, the successful companies of 2027 will be those that have moved beyond being simple vendors to becoming indispensable strategic partners that are deeply embedded in the daily lives of both providers and patients.
